1. Home
  2. FXACU vs WGSWW Comparison

FXACU vs WGSWW Comparison

Compare FXACU & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FXACU

FortuneX Acquisition Corporation Units

N/A

Current Price

$10.08

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Logo GeneDx Holdings Corp.

WGSWW

GeneDx Holdings Corp.

HOLD

Current Price

$0.00

Market Cap

0.0

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
FXACU
WGSWW
Founded
N/A
2017
Country
United States
United States
Employees
N/A
1300
Industry
Blank Checks
Retail: Computer Software & Peripheral Equipment
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
2026
N/A

Fundamental Metrics

Financial Performance
Metric
FXACU
WGSWW
Price
$10.08
$0.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
28.8K
56.8K
Earning Date
N/A
02-18-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$305,450,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
50.79
52 Week Low
$10.03
$0.00
52 Week High
$10.10
$0.13

Technical Indicators

Market Signals
Indicator
FXACU
WGSWW
Relative Strength Index (RSI) 54.76 39.97
Support Level $10.03 N/A
Resistance Level $10.10 $0.01
Average True Range (ATR) 0.02 0.00
MACD 0.00 -0.00
Stochastic Oscillator 52.63 17.98

Price Performance

Historical Comparison
FXACU
WGSWW

About FXACU FortuneX Acquisition Corporation Units

FortuneX Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: